Researchclinical trialsatopic dermatitiscorvus pharmaceuticalssoquelitinib
Corvus Pharmaceuticals Reports Positive Soquelitinib Trial Results
4.1
Corvus Pharmaceuticals reported updated Phase 1 results showing soquelitinib produced a 72% reduction in eczema severity versus 40% for placebo, according to an updated company report published this week. Shares fell 8.33% to $23.01 on Monday after a prior 212% rally; the company plans a Phase 2 trial in Q1 2026 to enroll 200 moderate-to-severe atopic dermatitis patients.
Key Points
- 1Demonstrates 72% eczema severity reduction in Phase 1 soquelitinib trial versus 40% placebo
- 2Triggers Phase 2 planning to enroll 200 patients across four dosing cohorts in Q1 2026
- 3Signals investor volatility after 212% rally; clinicians should await Phase 2 confirmation of efficacy
Scoring Rationale
Moderate novelty and official Phase 1 data, but narrow scope and low relevance to core AI/ML practitioners.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
